Statement of Investor Complaint under Reg. 13(3) of SEBI (LODR) Regulations, 2015 for Quarter ended December 31, 2016
Pfizer Ltd has informed BSE regarding Quarterly Statement on Investor Complaints / Grievances Redressal Mechanism for the Quarter ended December 31, 2016, under Regulation 13(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Shareholding for the Period Ended December 31, 2016
Pfizer Ltd has submitted to BSE the Shareholding Pattern for the Period Ended December 31, 2016. For more details, kindly Click here Details of meeting scheduled with an Analyst / Institutional Investor
Pfizer Ltd has informed BSE regarding "Details of meeting scheduled with an Analyst / Institutional Investor". Intimation of Schedule of Analyst / Institutional Investor Meetings
Pfizer Ltd has informed BSE regarding "Intimation of Schedule of Analyst / Institutional Investor Meetings". Pfizer fined $106 mn for 'unfair' prices of epilepsy drug
Flynn Pharma fined $6.55 million; CMA also ordered the companies to reduce their prices
Pfizer to relaunch Corex in new formulation
Pfizer will be launching a series of products as line extensions under the Corex brand name, starting with the first launch in December 2016 Updates
Pfizer Ltd has informed BSE that the Company has undertaken a comprehensive review of its respiratory offerings in order to better cover a broader range of indications through an expanded product portfolio. As a result of this review, the Company will launch additional products while it may also discontinue the manufacture of certain SKUs where needed.... Pfizer offers low-cost pneumonia shot
US pharmaceuticals giant Pfizer is to offer its pneumococcal vaccine at the lowest possible price to NGOs seeking to protect vulnerable people from illness in humanitarian crises. In what it... Transcript of the tele conference call with the Analysts
Pfizer Ltd has submitted to BSE a copy of "Transcript of the tele conference call with the Analysts".
Pfizer Q2 profit up 52% at Rs126 crore
Pfizer net sales rose to Rs552.08 crore for the July- September quarter, compared with Rs525.04 crore during the same period of previous fiscal